Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Trial ID or NCT#

NCT00831844

Status

not recruiting iconNOT RECRUITING

Purpose

This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

Official Title

A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors

Eligibility Criteria

Ages Eligible for Study: 7 Months to 30 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Neyssa Marina

Contact us to find out if this trial is right for you.

Contact

Peds Hem/Onc CRAs
650-723-5535